Jennifer R Brown

Jennifer R Brown

UNVERIFIED PROFILE

Are you Jennifer R Brown?   Register this Author

Register author
Jennifer R Brown

Jennifer R Brown

Publications by authors named "Jennifer R Brown"

Are you Jennifer R Brown?   Register this Author

100Publications

4141Reads

15Profile Views

Perceived risk for cancer progression and psychological status in chronic lymphocytic leukemia patients: CALGB 70603 (Alliance).

Leuk Lymphoma 2019 Oct 27;60(10):2580-2583. Epub 2019 Mar 27.

Division of Hematology, The Ohio State University Comprehensive Cancer Center , Columbus , OH , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1594218DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764912PMC
October 2019

Cardiovascular Toxicities Associated With Ibrutinib.

J Am Coll Cardiol 2019 Oct;74(13):1667-1678

Departments of Medicine and Pharmacology, Cardio-Oncology program, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2019.07.056DOI Listing
October 2019

For CLL cells, there's no place like home.

Leuk Lymphoma 2019 Aug 2:1-3. Epub 2019 Aug 2.

a Department of Medical Oncology, Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2019.1646910DOI Listing
August 2019

Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia - Passé Yet?

Hemasphere 2019 Aug 7;3(4):e275. Epub 2019 Aug 7.

Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/HS9.0000000000000275DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745924PMC
August 2019

Durable remissions with obinutuzumab-based chemoimmunotherapy: long-term follow-up of the phase 1b GALTON trial in CLL.

Blood 2019 02 28;133(9):990-992. Epub 2018 Dec 28.

CLL Research Consortium, Moores Cancer Center, UC San Diego Health, La Jolla, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-06-857714DOI Listing
February 2019

Ibrutinib: searching for a partner drug.

Lancet Oncol 2019 Jan 3;20(1):3-5. Epub 2018 Dec 3.

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(18)30861-1DOI Listing
January 2019

Vigilance for ibrutinib-associated ventricular arrhythmias: rare but be aware.

Leuk Lymphoma 2018 12 22;59(12):2767-2768. Epub 2018 Jul 22.

b CLL Center, Dana Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1482546DOI Listing
December 2018

Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

N Engl J Med 2018 12 1;379(26):2517-2528. Epub 2018 Dec 1.

From Ohio State University Comprehensive Cancer Center, Columbus (J.A.W., A.S.R., N.A.H., W.Z., K.A.R., G.L., J.S.B., H.G.O., J.C.B.); the Alliance Statistics and Data Center (A.S.R., A.M.B., B.M.-E., B.F., S.J.M.), Mayo Clinic (W.D., S.A.P., M.L.), Rochester, MN; Washington University School of Medicine, St. Louis (N.L.B.); Duke Cancer Institute, Duke University Medical Center, Durham (D.M.B., H.E.), and First Health of the Carolinas Cancer Center, Pinehurst (C.K.) - both in North Carolina; the University of Rochester Medical Center, Rochester, NY (P.M.B.); Stanford University School of Medicine, Stanford (S.C.), and the City of Hope Comprehensive Cancer Center, Duarte (A.H.) - both in California; Dana-Farber Partners CancerCare (J.R.B., R.M.S.) and the Massachusetts General Hospital Cancer Center (J.S.A.) - both in Boston; Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN (S.N.); University of Chicago Comprehensive Cancer Center (R.A.L.) and Loyola University Chicago (S.E.S.) - both in Chicago; the University of Calgary, Tom Baker Cancer Centre, Calgary, AB, Canada (C.O.); and the Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (R.F.L.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1812836DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325637PMC
December 2018

Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia.

Cancer Cell 2018 12 29;34(6):982-995.e7. Epub 2018 Nov 29.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Broad Institute of MIT & Harvard, Cambridge, MA 02142, USA; Novartis Institutes for Biomedical Research, 250 Massachusetts Avenue, Cambridge, MA 02139, USA. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108183048
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2018.11.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6298230PMC
December 2018

DUO delivers for duvelisib.

Authors:
Jennifer R Brown

Blood 2018 12;132(23):2422-2424

Dana-Farber Cancer Institute.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-10-879650DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284219PMC
December 2018

Relapsed CLL: sequencing, combinations, and novel agents.

Authors:
Jennifer R Brown

Hematology Am Soc Hematol Educ Program 2018 11;2018(1):248-255

CLL Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2018.1.248DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6245984PMC
November 2018

Pulsed gradient stimulated echo (PGStE) NMR shows spatial dependence of fluid diffusion in human stage IV osteoarthritic cartilage.

Magn Reson Med 2018 09 2;80(3):1170-1177. Epub 2018 Feb 2.

Molecular Biosciences Program, Montana State University, Bozeman, Montana, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mrm.27093DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980663PMC
September 2018

Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry.

Leuk Lymphoma 2018 08 22;59(8):1986-1989. Epub 2017 Nov 22.

e CLL Center and Department of Medical Oncology , Dana-Farber Cancer Institute, Harvard Medical School , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1397664DOI Listing
August 2018

Still a role for second-line chemoimmunotherapy in chronic lymphocytic leukemia?

Authors:
Jennifer R Brown

Haematologica 2018 07;103(7):1096-1098

CLL Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.196014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6029529PMC
July 2018

Ibrutinib: coming of age?

Authors:
Jennifer R Brown

Blood 2018 04;131(17):1880-1882

Dana-Farber Cancer Institute; Harvard Medical School.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-02-832071DOI Listing
April 2018

Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?

Expert Rev Hematol 2018 03 12;11(3):185-194. Epub 2018 Feb 12.

a Department of Medical Oncology , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2018.1435268DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6082118PMC
March 2018

Enhanced activation and expansion of T cells using mechanically soft elastomer fibers.

Adv Biosyst 2018 Feb 18;2(2). Epub 2018 Jan 18.

Department of Biomedical Engineering, Columbia University, New York, NY 10027, USA,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/adbi.201700167DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469863PMC
February 2018

How I treat CLL patients with ibrutinib.

Authors:
Jennifer R Brown

Blood 2018 01 18;131(4):379-386. Epub 2017 Dec 18.

Chronic Lymphocytic Leukemia Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-08-764712DOI Listing
January 2018

Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.

Ther Adv Hematol 2018 Jan 28;9(1):3-19. Epub 2017 Nov 28.

Dana-Farber Cancer Institute, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620717741861DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753924PMC
January 2018

Reply to S. Opat et al.

J Clin Oncol 2017 12 3;35(36):4094-4095. Epub 2017 Nov 3.

Jennifer R. Brown, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and Neil E. Kay, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.76.0652DOI Listing
December 2017

PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.

Expert Opin Investig Drugs 2017 Nov 6;26(11):1267-1279. Epub 2017 Oct 6.

a Department of Medical Oncology , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13543784.2017.1
Publisher Site
http://dx.doi.org/10.1080/13543784.2017.1384815DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747968PMC
November 2017

FCR achieves long-term durable remissions in patients with -mutated CLL.

Blood 2017 11 12;130(21):2278-2282. Epub 2017 Oct 12.

CLL Center, Division of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2017-07-731588DOI Listing
November 2017

The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.

Leuk Lymphoma 2017 Oct 9;58(10):2287-2297. Epub 2017 May 9.

b CLL Center, Department of Medical Oncology , Dana-Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2017.1312387DOI Listing
October 2017

Chemoimmunotherapy Is Not Dead Yet in Chronic Lymphocytic Leukemia.

J Clin Oncol 2017 09 25;35(26):2989-2992. Epub 2017 Jul 25.

Jennifer R. Brown, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and Neil E. Kay, Mayo Clinic, Rochester, MN.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.72.6810DOI Listing
September 2017

Targeting B Cell Signaling in Chronic Lymphocytic Leukemia.

Curr Oncol Rep 2017 Sep;19(9):61

Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-017-0620-7DOI Listing
September 2017

Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?

Expert Rev Hematol 2017 08 10;10(8):707-718. Epub 2017 Jul 10.

a Department of Internal Medicine , Oregon Health & Science University , Portland , OR , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1350166DOI Listing
August 2017

Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.

Drugs Aging 2017 07;34(7):509-527

CLL Center and Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40266-017-0468-4DOI Listing
July 2017

Ventricular arrhythmias and sudden death in patients taking ibrutinib.

Blood 2017 05 21;129(18):2581-2584. Epub 2017 Feb 21.

Division of Hematologic Malignancies and Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-10-742437DOI Listing
May 2017

Lenalidomide in the treatment of chronic lymphocytic leukemia.

Expert Opin Investig Drugs 2017 May 17;26(5):633-650. Epub 2017 Apr 17.

a Department of Medical Oncology , Dana Farber Cancer Institute , Boston , MA , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13543784.2017.1
Publisher Site
http://dx.doi.org/10.1080/13543784.2017.1313230DOI Listing
May 2017

Chemoimmunotherapy Versus Targeted Treatment in Chronic Lymphocytic Leukemia: When, How Long, How Much, and in Which Combination?

Am Soc Clin Oncol Educ Book 2016 ;35:e387-98

From the Dana-Farber Cancer Institute, Boston, MA; University Hospital of Cologne, Cologne, Germany; Swedish Cancer Institute, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_159018DOI Listing
January 2017

Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.

J Clin Oncol 2017 Jan 24;35(1):24-31. Epub 2016 Oct 24.

Alex F. Herrera, Matthew Mei, Lawrence Low, Joo Y. Song, Victoria Bedell, Lithua Budde, Wing C. Chan, Robert Chen, Joyce Murata-Collins, Auayporn P. Nademanee, Raju Pillai, Leslie Popplewell, Tanya Siddiqi, Jasmine Zain, Steven T. Rosen, Larry W. Kwak, Stephen J. Forman, Dennis D. Weisenburger, Young Kim, Amrita Krishnan, Tanya Paris, Tracey Stiller, Joycelynne M. Palmer, City of Hope National Medical Center, Duarte, CA; Haesook T. Kim, Jennifer R. Brown, Matthew S. Davids, Arnold S. Freedman, David C. Fisher, Eric D. Jacobsen, Caron A. Jacobson, Ann S. LaCasce, David M. Weinstock, Scott J. Rodig, Philippe Armand, Dana-Farber Cancer Institute; Gabriel K. Griffin, Reid W. Merryman, Christine Pak, Heather Sun, Brigham and Women's Hospital; German A. Pihan, Beth Israel Deaconess Medical Center; and Aliyah R. Sohani, Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.68.2740DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455688PMC
January 2017

Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.

Cancer Cell 2016 Nov 3;30(5):750-763. Epub 2016 Nov 3.

Department of Medical Oncology, Dana-Farber Cancer Institute, Dana 540, 44 Binney Street, Boston, MA 02115, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02141, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccell.2016.10.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127278PMC
November 2016

Using Targeted Inhibitors in the Management of Chronic Lymphocytic Leukemia: Are We There Yet?

Authors:
Jennifer R Brown

Oncology (Williston Park) 2016 11;30(11):1016, 1018

View Article

Download full-text PDF

Source
November 2016

The potential of venetoclax (ABT-199) in chronic lymphocytic leukemia.

Ther Adv Hematol 2016 Oct 8;7(5):270-287. Epub 2016 Jul 8.

Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5026291PMC
http://dx.doi.org/10.1177/2040620716655350DOI Listing
October 2016

Discovery of a Series of 5,11-Dihydro-6-benzo[]pyrimido[5,4-][1,4]diazepin-6-ones as Selective PI3K-δ/γ Inhibitors.

ACS Med Chem Lett 2016 Oct 2;7(10):908-912. Epub 2016 Aug 2.

Department of Cancer Biology, Dana-Farber Cancer Institute , Boston, Massachusetts 02215, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsmedchemlett.6b00209DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066161PMC
October 2016

The rosy future of BCL-2 inhibition in chronic lymphocytic leukemia: pursuit of a worthy target.

Authors:
Jennifer R Brown

Leuk Lymphoma 2015 18;56(10):2755-6. Epub 2015 Jun 18.

a Director, CLL Center, Department of Medical Oncology , Dana-Farber Cancer Institute and Department of Medicine, Harvard Medical School , Boston , MA , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2015.1048443DOI Listing
September 2016

Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.

Blood 2016 09 1;128(12):1609-13. Epub 2016 Aug 1.

Central European Institute of Technology, Masaryk University, Brno, Czech Republic; Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-04-709519DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291297PMC
September 2016

The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.

Blood 2016 06 11;127(25):3215-24. Epub 2016 Apr 11.

Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia; Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, Australia; Department of Clinical Hematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Parkville, VIC, Australia;

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2016-01-68
Publisher Site
http://dx.doi.org/10.1182/blood-2016-01-688796DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4920022PMC
June 2016

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.

Blood 2016 06 3;127(25):3237-52. Epub 2016 May 3.

Department of Medical Oncology, Bing Center for Waldenstrom's Macroglobulinemia, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2016-01-695098DOI Listing
June 2016

Physical Examination for the Academic Psychiatrist: Primer and Common Clinical Scenarios.

Acad Psychiatry 2016 Apr 18;40(2):321-7. Epub 2015 Apr 18.

Tufts University School of Medicine, Burlington, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40596-015-0334-9DOI Listing
April 2016

The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.

Authors:
Jennifer R Brown

Semin Oncol 2016 Apr 8;43(2):260-4. Epub 2016 Feb 8.

CLL Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2016.02.004DOI Listing
April 2016

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

N Engl J Med 2016 Jan 6;374(4):311-22. Epub 2015 Dec 6.

From the Department of Clinical Haematology and the Bone Marrow Transplantation Unit, Royal Melbourne Hospital (A.W.R., M.A.A.), the Division of Cancer and Haematology, Walter and Eliza Hall Institute of Medical Research (A.W.R., M.A.A.), and the Victorian Comprehensive Cancer Centre (A.W.R., J.F.S.), Parkville, VIC, and the University of Melbourne (A.W.R., J.F.S.) and Peter MacCallum Cancer Centre (J.F.S.), Melbourne, VIC - all in Australia; Dana-Farber Cancer Institute, Boston (M.S.D., J.R.B.); the Swedish Medical Center, Seattle (J.M.P.); Washington University, St. Louis (B.S.K.); University of Arizona, Tucson (S.D.P.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York (J.F.G.); University of California, San Diego, San Diego (T.J.K.); AbbVie, North Chicago, IL (L.G., S.W., M.D., M.Z., M.B.D., E.C., S.H.E., R.A.H.); and University of Texas M.D. Anderson Cancer Center, Houston (W.G.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1513257DOI Listing
January 2016

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

N Engl J Med 2016 Jan 7;374(4):323-32. Epub 2015 Dec 7.

From the Division of Hematology, Department of Internal Medicine, Ohio State University (J.C. Byrd, J.A.J., F.T.A., J.W., A.J.J.), and the Department of Veterinary Biosciences, College of Veterinary Medicine (B.H.) - both in Columbus; UC Irvine Health Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange (S.O.); University of Oxford, Oxford (A.S.), NHS Foundation Trust, King's College Hospital, London (S.D.), and the Department of Haematology, St. James's University Hospital, Leeds (P.H.) - all in the United Kingdom; Northwest Medical Specialties, Tacoma (J.C.), and the Swedish Cancer Institute, Seattle (J.M.P.) - both in Washington; the Department of Leukemia, Division of Cancer Medicine, University of Texas, and M.D. Anderson Cancer Center - both in Houston (W.G.W.); the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston (J.R.B.); Huntsman Cancer Institute, University of Utah, Salt Lake City (D.M.S.); Università Vita-Salute San Raffaele and Istituto Scientifico San Raffaele, Milan (P.G.); Hofstra North Shore-LIJ School of Medicine, Chronic Lymphocytic Leukemia Research and Treatment Center, Lake Success (J.C. Barrientos), and the Department of Pathology and Cell Biology, Columbia University Medical Center (T.G.D.), and New York-Presbyterian/Weill Cornell Medical Center, New York (R.R.F.) - all in New York; and Acerta Pharma, Oss, the Netherlands (D.J., J.H., X.W., A.K., B.J.L., T.C., M.F., J.M., A.H., W.R., R.I.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1509981DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862586PMC
January 2016

Idelalisib has CLL on the run!

Authors:
Jennifer R Brown

Blood 2015 Dec;126(25):2656-7

DANA-FARBER CANCER INSTITUTE.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-10-676890DOI Listing
December 2015

Pattern of cardiac surveillance among patients with lymphoma receiving anthracycline-based chemotherapy.

BMJ Open 2015 Oct 6;5(10):e008350. Epub 2015 Oct 6.

Division of Cardiology, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2015-008350DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4606381PMC
October 2015

Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort.

Br J Haematol 2015 Sep 1;170(5):694-703. Epub 2015 Jun 1.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13498DOI Listing
September 2015

Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Chemotherapy.

Authors:
Jennifer R Brown

Oncology (Williston Park) 2015 Jun;29(6):442, 444

View Article

Download full-text PDF

Source
June 2015

Targeting neddylation effectively antagonizes nuclear factor-κB in chronic lymphocytic leukemia B-cells.

Leuk Lymphoma 2015 May;56(5):1566-9

Norris Cotton Cancer Center, Dartmouth-Hitchcock Medical Center , Lebanon, NH , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.990901DOI Listing
May 2015